Happy Mothers’ Day to all of you who are moms, aunts, grandmothers, people with moms, pet moms! Here’s a special Mothers’ Day edition about Fiasp!
Novo Nordisk’s Ultra-Fast Rapid-Acting Insulin Fiasp Approved in Europe and Canada, announced on Nasdaq GlobeNewswire, 10 January 2017. Why am I just writing about this today? Well, it’s available in Canada and reasonable prices … and coming to the US hopefully by end of 2017! And from what I hear, it works very well! Read the release: Fiasp® (fast-acting insulin aspart) approved in Europe
Here are some highlights by Mike Hoskins from DiabetesMine:
- FIASP is not the most creative branding (sounds like a variety of wasps?), but the name certainly fits. Whether it will carry a new brand name here States when launched remains TBD.
- Internationally, FIASP is available by vial, Penfill, and FlexTouch insulin pen. In Europe it’s approved for insulin pumps but not in Canada. Here in the U.S., Novo tells us FIASP will only be available in pen form.
- While Novo officially still recommends taking FIASP before the meal, overall they’re touting more flexible dosing, mentioning “earlier, greater and faster absorption, thereby providing earlier insulin action.”
- It’s twice as fast as regular NovoLog or NovoRapid. Getting into the science, that’s because two “excipients” have been added to FIASP’s formulation — Vitamin B3 (niacinamide) to increase the speed of absorption, and a naturally occurring Amino Acid (L-Arginine) for stability.
- Data also show that patients lowered their A1C levels.
Read LOTS more including reviews from patients: The Scoop on Novo’s New Faster-Acting FIASP Insulin